Valens Research Weekly Equity Idea Highlight for September 13, 2017 – Gilead Sciences, Inc.

This week the Valens Securities team highlights our most interesting equity insight from across our tools and our analysis.

Management’s success in operating their core business, intelligent acquisitions to drive growth, low market expectations and growing management confidence in their outlook are a diagnosis for equity upside

The market is expecting GILD to see significant declines in ROA’ going forward, to the low end of peer profitability levels, from current best in class levels, with slower growth also. The company currently trades at the low end of historic valuations and the low end of peer valuations, highlighting the market’s pessimism.

Click here to read the article in its entirety.